Published Date: 04 Jun 2025
For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted therapy, reduces the frequency of vasomotor symptoms, ...
Read Full NewsPaul Melmeyer, MPP, executive vice president, public policy and advocacy, Muscular Dystrophy Association, explains how adding Duchenne muscular dystrophy to the Recommended Unified Screening Panel reshapes early diagnosis, treatment timing, and family counseling.
The HCPFive: Top News for Healthcare Providers from the Week of 01/11
1.
X-ray and radar technology combined to reduce cancer screening risks
2.
Prostate cancer early detection system eliminates need for biopsy.
3.
Surviving cancer, still suffering: Survey reveals gaps in follow‑up care
4.
Breast cancer prevention: How nurse practitioners and physician assistants can help
5.
Weight loss trial reports success for breast cancer patients at one year mark
1.
Beyond the Tumor: Emerging Frontiers in Cancer Systems Biology
2.
Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers
3.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
4.
Precision to Personalization: Expanding Genetic Testing and Counseling in Oncology
5.
Introduction To Immune Thrombocytopenic Purpura
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XIV
2.
Navigating the Complexities of Ph Negative ALL - Part I
3.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
4.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation